AbbVie Inc. (ABBV) vs AstraZeneca PLC (AZN)
A side-by-side comparison of AbbVie Inc. and AstraZeneca PLC across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 10, 2026. Differences are shown without an overall score or investment verdict.
ABBV
AbbVie Inc.
$257.06HealthcareDelayed quote: Sep 11, 2026, 4:00 PM EDT
AZN
AstraZeneca PLC
$160.17HealthcareDelayed quote: Sep 11, 2026, 4:00 PM EDT
Total return — ABBV vs AZN
growth of $100 · dividends reinvested · last 10yABBV +507.0% (+19.8%/yr)AZN +228.1% (+12.6%/yr)ABBV compounded faster over this window
ABBV AZN
ABBV vs AZN: by the numbers
- •ABBV is the larger company ($454.17B vs $248.40B market cap).
- •AZN trades at the lower trailing earnings multiple (24.05 vs 72.43 P/E), one valuation lens rather than an overall verdict.
- •AZN converts more revenue to profit (17.02% vs 9.81% net margin).
- •AZN grew revenue faster over the past five years (15.76% vs 3.69% CAGR).
- •ABBV pays the higher dividend yield (2.68% vs 2.02%).
Metrics side by side
Valuation
| Metric | ABBV | AZN |
|---|---|---|
| P/E ratio | 72.43 | 24.05 |
| Forward P/E | 18.32 | 15.64 |
| P/S ratio | 7.05 | 4.05 |
| P/B ratio | N/A | 4.94 |
| EV / EBITDA | 19.34 | 13.56 |
| FCF yield | 3.99% | 3.52% |
Profitability
| Metric | ABBV | AZN |
|---|---|---|
| Gross margin | 71.48% | 81.88% |
| Operating margin | 29.32% | 22.77% |
| Net margin | 9.81% | 17.02% |
| ROE | N/A | 20.79% |
| ROIC | 13.46% | 12.83% |
Dividends
| Metric | ABBV | AZN |
|---|---|---|
| Dividend yield | 2.68% | 2.02% |
| Payout ratio | 192.43% | 48.50% |
Growth (annualized)
| Metric | ABBV | AZN |
|---|---|---|
| Revenue CAGR (5Y) | 3.69% | 15.76% |
| EPS CAGR (5Y) | -2.79% | 22.02% |
| FCF CAGR (5Y) | 0.11% | 14.53% |
| Total return CAGR (5Y) | 23.51% | 9.46% |
Frequently asked
- Which has the lower trailing P/E, ABBV or AZN?
- AZN has the lower trailing P/E: ABBV trades at 72.43 and AZN at 24.05. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, ABBV or AZN?
- Over the past five years, AZN grew revenue faster — ABBV at a 3.69% CAGR versus AZN at 15.76%.
- Does ABBV or AZN pay a bigger dividend?
- ABBV yields 2.68% and AZN yields 2.02% based on trailing dividends and the latest price.
- Is ABBV or AZN more profitable?
- AZN runs the higher net margin — ABBV at 9.81% versus AZN at 17.02%.
- How have ABBV and AZN total returns compared?
- Over the past 10 years, ABBV delivered 19.76% and AZN delivered 12.85% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
AbbVie P/E ratioAstraZeneca P/E ratioAbbVie dividend yieldAstraZeneca dividend yieldAbbVie ROEAstraZeneca ROEAbbVie operating marginAstraZeneca operating marginAbbVie revenue growthAstraZeneca revenue growthAbbVie free cash flowAstraZeneca free cash flow
AbbVie & AstraZeneca appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 10, 2026.